Trial Profile

A global pivotal trial of FT011 as a treatment for scleroderma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 21 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FT 011 (Primary)
Indications Systemic scleroderma
Focus Registrational; Therapeutic Use
Sponsors Certa Therapeutics

Most Recent Events

21 Nov 2023 New trial record
15 Nov 2023 According to a Certa Therapeutics media release, this trial has supported by global clinical experts, the clinical trial design and associated development plans will be discussed with the FDA in early-2024, with complementary scientific advice sought from the EMA mid-2024. The company intends to start the pivotal study in late-2024.
15 Nov 2023 According to a Certa Therapeutics media release, company is in preparation for a global pivotal trial of FT011 as a treatment for scleroderma.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com